This inventor holds 3 USPTO granted patents. Top assignees: Dr. Reddy's Laboratories, Incorporated, Avyxa Holdings, LLC. Active years: 2020-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2025
Title: Svb Janardhan Garikipati: Innovator in Pharmaceutical Formulations
Introduction
Svb Janardhan Garikipati is a notable inventor based in Visakhapatnam, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of stable liquid formulations for cancer treatment. With a total of three patents to his name, Garikipati's work is recognized for its potential impact on patient care.
Latest Patents
Garikipati's latest patents focus on stable liquid formulations of cyclophosphamide. These formulations comprise cyclophosphamide and at least one pharmaceutically acceptable excipient, with a moisture content of less than about 2.0% by weight. The invention outlines a process for reducing moisture content from cyclophosphamide or its liquid compositions. Furthermore, it details methods for using these stable formulations for parenteral administration, either as ready-to-use or ready-to-dilute options for treating various cancer disorders.
Career Highlights
Throughout his career, Garikipati has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Dr. Reddy's Laboratories and Avyxa Holdings. His experience in these organizations has contributed to his expertise in pharmaceutical formulations and innovation.
Collaborations
Garikipati has collaborated with several professionals in his field, including Riyaz Ahmed Shaik and Ananya Saha. These collaborations have likely enhanced his research and development efforts, leading to successful innovations.
Conclusion
Svb Janardhan Garikipati is a distinguished inventor whose work in stable liquid formulations of cyclophosphamide has the potential to improve cancer treatment options. His contributions to the pharmaceutical industry reflect a commitment to innovation and patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
